非小细胞肺癌与结直肠癌患者KRASG12C突变状态的[18F]PFPMD首次人体PET显像
本研究基于索托拉西布(AMG510)开发靶向KRASG12C的PET示踪剂[18F]PFPMD,经细胞与小动物PET/CT验证后,在5名健康志愿者中评估安全性、生物分布与剂量学,并对14例伴或不伴KRASG12C突变的非小细胞肺癌或结直肠癌患者行[18F]PFPMD与[18F]FDG PET/CT显像;结果显示[18F]PFPMD安全、主要经胆囊和肠道排泄,KRASG12C突变肿瘤摄取显著高于非突变肿瘤。
要点
- [18F]PFPMD在KRASG12C突变肿瘤中摄取显著高于非突变肿瘤,患者SUVmax 3.73±0.58 vs 2.39±0.22(P<0.01)。
- [18F]PFPMD在人体安全,主要经胆囊和肠道排泄,全身有效剂量与[18F]FDG相当。
- 作者认为[18F]PFPMD是用于无创筛查NSCLC和CRC患者KRASG12C突变状态的安全且有前景的PET示踪剂。
核心结论
- [18F]PFPMD是用于无创筛查非小细胞肺癌和结直肠癌患者KRASG12C突变状态的安全且有前景的PET示踪剂。
研究设计与样本
- 基于AMG510(索托拉西布)在喹唑啉酮结构上连接聚乙二醇链合成[18F]PFPMD。
- 通过细胞摄取、内化及阻断实验(H358为KRASG12C突变,A549为非KRASG12C突变)及荷瘤小鼠小动物PET/CT验证结合选择性与显像潜力。
- 纳入5名健康志愿者评估[18F]PFPMD的安全性、生物分布与剂量学。
- 14例伴或不伴KRASG12C突变的非小细胞肺癌或结直肠癌患者接受[18F]PFPMD与[18F]FDG PET/CT显像。
主要发现
- [18F]PFPMD放射化学产率高、放射化学纯度高且稳定性好,蛋白结合实验显示其选择性结合KRASG12C蛋白。
- 细胞摄取:H358为3.22%±0.28%,A549为2.50%±0.25%(P<0.05);AMG510阻断后H358为2.06%±0.13%(P<0.01)。
- 荷瘤小鼠PET:H358为3.93%±0.24%ID/g,A549为2.47%±0.26%ID/g(P<0.01);阻断组为2.89%±0.29%ID/g(P<0.05)。
- [18F]PFPMD在人体安全,主要经胆囊和肠道排泄,全身有效剂量与[18F]FDG相当。
- NSCLC和CRC患者中KRASG12C突变肿瘤摄取显著高于非突变肿瘤(SUVmax 3.73±0.58 vs 2.39±0.22,P<0.01)。
临床怎么用
- 原文结论认为[18F]PFPMD是用于无创筛查NSCLC和CRC患者KRASG12C突变状态的安全且有前景的PET示踪剂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Kirsten rat sarcoma (KRAS) mutations are an important marker for tumor-targeted therapy. In this study, we sought to develop a KRASG12C oncoprotein-targeted PET tracer and to evaluate its translational potential for noninvasive imaging of the KRASG12C mutation in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) patients. Methods: [18F]PFPMD was synthesized on the basis of AMG510 (sotorasib) by attaching a polyethylene glycol chain to the quinazolinone structure. The binding selectivity and imaging potential of [18F]PFPMD were verified by cellular uptake, internalization, and blocking (H358: KRASG12C mutation; A549: non-KRASG12C mutation) studies, as well as by a small-animal PET/CT imaging study on tumor-bearing mice. Five healthy volunteers were enrolled to assess the safety, biodistribution, and dosimetry of [18F]PFPMD. Subsequently, 14 NSCLC or CRC patients with or without the KRASG12C mutation underwent [18F]PFPMD and [18F]FDG PET/CT imaging. The SUVmax of tumor uptake of [18F]PFPMD was measured and compared between patients with and without the KRASG12C mutation. Results: [18F]PFPMD was obtained with a high radiochemical yield, radiochemical purity, and stability. The protein-binding assay showed that [18F]PFPMD selectively binds to the KRASG12C protein. [18F]PFPMD uptake was significantly higher in H358 than in A549 and was decreased by pretreatment with AMG510 (H358 vs. A549: 3.22% ± 0.28% vs. 2.50% ± 0.25%, P < 0.05; block: 2.06% ± 0.13%, P < 0.01). Similar results were observed in tumor-bearing mice on PET imaging (H358 vs. A549: 3.93% ± 0.24% vs. 2.47% ± 0.26% injected dose/g, P < 0.01; block: 2.89% ± 0.29% injected dose/g; P < 0.05). [18F]PFPMD was safe in humans and was excreted primarily by the gallbladder and intestines. The whole-body effective dose was comparable to that of [18F]FDG. The accumulation of [18F]PFPMD in KRASG12C mutation tumors was significantly higher than that in non-KRASG12C mutation tumors (SUVmax: 3.73 ± 0.58 vs. 2.39 ± 0.22, P < 0.01) in NSCLC and CRC patients. Conclusion: [18F]PFPMD is a safe and promising PET tracer for noninvasive screening of the KRASG12C mutation status in NSCLC and CRC patients.
引用
- Li X, Ye J, Wang J, et al. First-in-Humans PET Imaging of KRASG12C Mutation Status in Non-Small Cell Lung and Colorectal Cancer Patients Using [18F]PFPMD. J Nucl Med. 2023. PMID: 37827842. doi:10.2967/jnumed.123.265715
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。